Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

SHELTON, Conn., Aug. 5 /PRNewswire/-- Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical analgesic activity. In addition, CR845 infusion triggered a quantitative endocrine biomarker of peripheral kappa opioid receptor activation at the lowest dose tested.

The Phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 resulted in plasma levels at or above the plasma levels of drug expected to be associated with clinical analgesic efficacy.

The Company plans to advance its intravenous formulation of CR845 into Phase II trials later in 2008. Based on the demonstrated safety, tolerability, and bioactivity of this formulation in Phase I, Cara will continue to develop its oral formulation of CR845 for advancement into Phase I.

About CR845

CR845 was designed to be highly selective for the peripheral kappa opioid receptor, with a prolonged duration of action relative to Cara's first generation of peripheral kappa opioids. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intravenous, subcutaneous, o
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)....J.,Nov.24/PRNewswire-FirstCall/--QuestDiagnostics...ofdiagnostictesting,informationandservices,announc...rayHealthcareConferenceinNewYorkCity.Thepresentati...EasternTime. ,, Duringtheconference,thecompanyw...imate3%,operatingincometoexceed18%ofrevenues,anddi...
(Date:11/24/2009)...LAKE,N.J.andNEWYORK,Nov.24/PRNewswire/-- EisaiInc...dministration(FDA)hasacceptedforreviewEisai,sNewDr...nepezilHClextendedrelease)tabletsforthetreatmentof...erdoseformulationcontains23mgofdonepezilHClinanext...hatallowsforgradualreleaseofthedrug.TheNDAisbasedo...
(Date:11/24/2009)...Nov.24/PRNewswire/--Accumetrics,Inc.,aprivately-he...hefirstrapidandeasy-to-usediagnosticsystemformeasu...ents(e.g.Plavix®andaspirin),announcedtodaytha...egoryJ.Tibbitts,ChiefFinancialOfficerofAccumetrics...PiperJaffrayHealthCareConferencebeingheldinNewYork...
Breaking Medicine Technology:Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Pesticides easier detection of pollution and impact in rivers 9791 1Pesticides easier detection of pollution and impact in rivers 9791 2Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 56259 1Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 56259 2Swine Flu Vaccine Seems Safe 3A Experts 56255 1Swine Flu Vaccine Seems Safe 3A Experts 56255 2Swine Flu Vaccine Seems Safe 3A Experts 56255 3
...ug. 8 On August 7, J. J.,Finkelstein, Chief Execu...,RGN) updated the investment community in an all-n...covered in the interview include RegeneRx,Biopharm...petitive edge,recent news, and milestones for whic...n its entirety, visit http://www.wallst.net, and...
...G, Md., Aug. 9 Iomai Corporation,(Nasdaq: IOMI )... 1 safety,and immunogenicity trial of its patch-ba... subjects who received the vaccine -- 19 elderly a...onse, demonstrating that even elderly,subjects wit...he trial was designed to compare the number of eld...
Other Medicine Technology:WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals' CEO 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 4
(Date:11/25/2009)...5/PRNewswire/--Thanksgivingmealswillbedeliveredtoa...eachareathankstoFaithInAction/VolunteerActionforAg...isionofSCANHealthPlan.Formorethan17yearstheseorgan...armThanksgivingmealstoseniorsinneedinLongBeach,Lak...ndingcities. ,, "Ourwarmholidaymealsaredelivere...
(Date:11/25/2009)...wswire-USNewswire/--TheBlackAIDSInstituterecentlyh...dershipfor2010. ,, ThenewBoardMembersareahighly...,law,finance,governmenthealthprograms,editorial,an...derangeofpersonalbackgroundsincludingbothheterosex...ves,andrepresentingmultipleagegroups. ,, (Photo...
(Date:11/25/2009)...ments,Business,andPressJoinEfforttoEducate ,, ...gain,theNationalBipolarFoundationandtheMedicAlertF...ilStable"program,whichisnowbeingwidelyacceptedasap...,theNationalBipolarFoundationreceivedaproclamation...t.GovernorofLouisianaMitchLandrieu.TheNationalBipo...
(Date:11/25/2009)...nce of a statistically significant survival benefi...rogen receptor (ER)-positive tumors had high level...R-alpha S118-P), according to a brief communicatio...the National Cancer Institute . , Approximately ...n. Preclinical studies have shown that ER-alpha S1...
(Date:11/25/2009)...ressure? This simple question has been the focus ...lated gene Modulates High Blood Pressure in Mice &...simple question has been the focus of intense rese... first time established a link between a novel gen...tress in mice as well as humans. The studies were ...
Breaking Medicine News(10 mins):Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2
...Dec. 11 According to survey results released,toda...cipants were asked,what guidelines they follow for...d metabolic risk factors, the largest group of res...cardiology, endocrinology, nephrology,and primary ...
...uth Plantation High School One of the 25 Healthies...untry, FT. LAUDERDALE, Fla., Dec. 11 The ,got mi...iation with the School Nutrition,Association and t...schools in the nation. The recognition is a result...
...E CITY, Dec. 11 Amedica Corporation, an,orthopedi...mic,technologies, announced today that the U.S. Fo...10(k) marketing clearance for Amedica,s Valeo(TM),...of the thoracolumbar spine.,The Valeo VBR incorpor...
...dy finds the more red meat and processed meat you ... 11 (HealthDay News) -- A quarter-pound hamburger ...increased risk for a variety of cancers, U.S. gove...titute concluded. , "Red and processed meats have...
... Calif., Dec. 11 Panomics Inc., a,developer of in...antitative,Biology (PQB)(TM), and the exclusive pr...ducts for gene expression measurement and profilin...ard. Frost & Sullivan, a global consulting firm, p...
..., Dec. 10 The holiday season is a time for,office...ine high-calorie,goodies with the cold winter weat... Derek Gallup, Fitness Operations VP at 24 Hour Fi...ur Fitness at:, http://media.medialink.com/WebNR.a...
Other Medicine News:Health News:With Obesity, Diabetes, and Cardiovascular Disease on the Rise, Physicians Need More Comprehensive Guidelines 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 3Health News:High Meat Consumption Linked to Heightened Cancer Risk 4Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 3
Creatine Kinase (CK-MB) ROSALKI
Cholesterol (CHOD-PAP) (DIMENSION)
Alanine Aminotransferase (ALT) Liquid
...adable Anteroir Cervical System, in conjunction wi...nservative treatment with a collar), is intended f...y and fusion procedures as a means to maintain the...ografts., This device is not intended to be u...
Medicine Products: